ENvue Medical Lands $50M Equity Line and Upsizes Preferred Facility to $59M in Fight to Stay on Nasdaq

summarizeSummary

ENvue Medical announced a $50M equity line of credit and a $59M upsized preferred stock facility, both with deeply dilutive pricing mechanisms, as it fights to maintain its Nasdaq listing and address its going-concern warning.

check_boxKey Events · Financing and Capital Events · FEED

• $50M Committed Equity Facility

  Through a Common Shares Purchase Agreement with an institutional investor, ENvue Medical gains the right to sell up to $50 million of common stock over 36 months at a price equal to 90% of the lowest VWAP during the three trading days preceding each sale.

• Series H Facility Upsized to $59M

  An amendment to the existing Series H Convertible Preferred Stock purchase agreement increases total Additional Investment Rights to $59 million Stated Value ($53.1 million Subscription Amount), with a minimum exercise requirement of $10 million over 12 months.

• Mandatory Series X Redemption

  Both the equity line and the amended Series H facility require 40% of net proceeds to be used to redeem outstanding Series X Preferred Stock until none remains, prioritizing the exit of a specific holder.

• Deeply Dilutive Pricing

  The equity line sells shares at a 10% discount to the lowest VWAP over three days, while the Series H conversion price is set at 85% of the three lowest VWAPs in the prior 10 days—both structures could cause significant dilution if utilized.

auto_awesomeAnalysis · FEED · Industrial Applications And Services

Facing a Nasdaq delisting notice and a going-concern warning, ENvue Medical has entered into a $50 million committed equity facility and amended an existing preferred stock deal to raise total potential funding to $59 million. The equity line lets the company sell shares at a 10% discount to the lowest VWAP over three days—a deeply dilutive structure that could more than double the outstanding share count if fully utilized. Under the amended Series H facility, the investor must now purchase at least $10 million of preferred stock over the next 12 months, providing a backstop but at a conversion price set at 85% of the three lowest VWAPs in the prior 10 days. Both agreements mandate that 40% of net proceeds be used to redeem outstanding Series X Preferred Stock, prioritizing the exit of a specific holder. This financing package is a high-stakes survival move: it provides critical cash runway but at the cost of severe potential dilution, especially with the stock trading near $0.42 and a reverse split vote scheduled for August 14, 2026.